BioMS and Lilly discontinue dirucotide after Phase III trial fails
28 July 2009
Katie McQue
BioMS and
Lilly have discontinued the development programme of their potential multiple sclerosis therapy dirucotide after it failed to meet the primary endpoint of a two-year Phase III trial in secondary progressive MS.
This has come as a huge blow to BioMS, for dirucotide was its only clinical...
Please Login to read the full article.
28 July 2009
Katie McQue
This has come as a huge blow to BioMS, for dirucotide was its only clinical...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Coronado gets $25.8 million boost to pursue parasite-based autoimmune disease therapy
- US FDA denies Teva's plea to reject generic Copaxone apps
- Bravo or bravado? Teva, Active move baseline to make PhIII oral MS miss a hit
- Acetylon raises $27M to test selective HDAC inhibitor in clinic for cancer
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
